The Big Heart Disease Lie

Heart Disease No More

Get Instant Access

1. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-414.

2. Conti CR, Brawley RK, Griffith LSC, et al. Unstable angina pectoris: morbidity and mortality in 57 consecutive patients evaluated angiographically. Am J Cardiol 1973;32:745-750.

3. Fuster V Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-1220.

4. Fuster V Badimon L, Badimon JJ, Chesebro JH. The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50,310-318.

5. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1985;71:699-708.

6. Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989;80: 198-205.

7. Falk E, Shah PK, Fuster V Coronary plaque disruption. Circulation 1995;92:657-671.

8. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.

9. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMIIIIB Trial. Circulation 1994;89:1545-1556.

10. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, 1994.

11. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.

12. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I findings. N Engl J Med 1985;312:932-936.

13. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q wave myocardial infarction. N Engl J Med 1986;315:417-423.

14. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993;87:38-52.

15. Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute interventions. J Am Coll Cardiol 1994;24:616-623.

16. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Unstable Angina and Non-ST Segment Elevation Myocardial Infarction). J Am Coll Cardiol 2000;36:970-1056.

17. Chester MR, Chen L, Kaski JC. Angiographic evidence for frequent "silent" plaque disruption in patients with stable angina. J Am Coll Cardiol 1995;Special Issue:428A.

18. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015-2025.

19. Webster MWI, Chesebro JH, Smith HC, et al. Myocardial infarction and coronary artery occlusion: a prospective 5-year angiographic study. J Am Coll Cardiol 1990;15:218A.

20. Davies MJ. The composition of coronary-artery plaques. N Engl J Med 1997;336:1312-1314.

21. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gertenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986;1986:1214-1219.

22. Rocco MB, Nabel EG, Campbell S, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with coronary artery disease. Circulation 1988;78:877-884.

23. Fung AY, Jue J, Thompson CR, Davies C, Schreiber WE. Diagnosis of microinfarction in acute ischemic syndromes is of prognostic value. J Am Coll Cardiol 1994;Special Issue:316A.

24. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of troponin T in unstable angina. N Engl J Med 1992;327:146-150.

25. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349.

26. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405-2412.

27. Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med 1990;19:179-186.

28. National Heart Attack Alert Program Coordinating Committee—60 Minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311-329.

29. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. 9-11: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13: 188-195.

30. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Staffing and equipping emergency medical services systems: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:58-65.

31. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Emergency medical dispatching: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:67-73.

32. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497.

33. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.

34. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-3097.

35. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094.

36. Ault K, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary: results from the TIMI 12 trial. J Am Coll Cardiol 1999;33:634-639.

37. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.

38. Becker RC, Tracy RP, Bovill EG, et al. Surface 12-lead electrocardiogram findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest. J Thromb Thrombolysis 1994;1:101-107.

39. Davies MJ, Thomas A. Plaque fissuring—the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-373.

40. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1998;92:1565-1569.

41. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979 [published erratum appears in N Engl J Med 1997;337:356].

42. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reative protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-172.

43. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.

44. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466.

45. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-1465.

46. Cannon CP, Weintraub WS, Demopoulos L, et al. High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: primary results of the TACTICS-TIMI 18 C-Reactive Protein substudy. J Am Coll Cardiol 2001;37(Suppl. A):315A.

47. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydiapneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87:1130-1134.

48. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-986.

49. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268:68-72.

50. Blasi F, Cosentini R, Raccanelli R, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997;112:309-312.

51. Danesh J, Collins R, Peto R. Chronic infection and coronary heart disease: is there a link? Lancet 1997; 350:430-436.

52. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997;96:4095-4103.

53. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet 1997;350: 404-407.

54. Gupta S, Leathan EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-407.

55. Sinisalo J, Mattila K, Valtonen V et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002;105:1555-1560.

56. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with Zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis 2000;181(Suppl. 3):S572-S578.

57. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:913-919.

58. Brunelli C, Spallarossa P, Ghigliotta G, Ianetti M, Caponnetto S. Thrombosis in refractory unstable angina. Am J Cardiol 1991;68:110B-118B.

59. Uchida Y, Fujimori Y, Hirose J, Oshima T. Percutaneous coronary angioscopy. Jpn Heart J 1992;33: 271-294.

60. Mizuno K, Satumo K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287-291.

61. Sullivan E, Kearney M, Isner JM, Topol EJ, Losordo DW. Pathology of unstable angina: analysis of biopsies obtained by directional coronary atherectomy. J Thromb Thrombolysis 1994;1:63-71.

62. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986;7:472-478.

63. Ambrose JA, Hjemdahl-Monsen CE, Borrico S, Gorlin R, Fuster V Angiographic demonstration of a common link between unstable angina and non-Q-wave myocardial infarction. Am J Cardiol 1988;61: 244-247.

64. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.

65. Theroux P, Latour JG, Leger-Gautier C, Delaria J. Fibrinopeptide A and platelet factor four levels in unstable angina. Circulation 1987;75:156-162.

66. Robertson RM, Robertson D, Roberts LJ, et al. Thromboxane A2 in vasotonic angina pectoris. N Engl J Med 1981;304:998-1003.

67. Alexopoloulos D, Ambrose JA, Stump D, et al. Thrombosis-related markers in unstable angina. J Am Coll Cardiol 1991;17:866-871.

68. Hirsch PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and throm-boxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981;304: 685-691.

69. van der Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina complex coronary lesion morphology. Circulation 1989;79:116-124.

70. Becker RC, Tracy RP, Bovill EG, Mann KG, Ault K, for the TIMI-III Thrombosis and Anticoagulation Study Group. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Coron Artery Dis 1994;5:339-345.

71. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396-403.

72. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-1375.

73. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988;319:1105-1111.

74. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.

75. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-2048.

76. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994;89:81-88.

77. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276: 811-815.

78. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.

79. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfrac-tionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.

80. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable Angina/Non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.

81. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.

82. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.

83. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.

84. Mazzoli S, Tofani N, Fantini A, et al. Chlamydiapnermoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998;135:15-20.

85. Becker RC, Bovill EG, Corrao JM, et al. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q wave myocardial infarction. J Thromb Thrombolysis 1994;1:95-100.

86. Becker RC, Bovill EG, Corrao JM, et al. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction. J Thromb Thrombolysis 1995;2:57-64.

87. Trip MD, Manger Cats V can Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-1554.

88. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-1518.

89. Van Belle E, Lablanche J-M, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angio-scopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis. Circulation 1998;97:26-33.

90. Inoue K, Ochiai H, Kuwaki K. The mechanism of reocclusion after successful coronary thrombolysis as validated by percutansous angioscopy. J Am Coll Cardiol 1994:13A.

91. Braunwald E. The open-artery theory is alive and well—again. N Engl J Med 1993;329:1650-1652.

92. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation 1989;79:441-444.

93. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.

94. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.

95. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56: 786-794.

96. Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction. Comparison with conventionally treated patients. Clin Cardiol 1979;2:92-105.

97. Ganz W, Buchbinder N, Marcus H, et al. Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 1981;101:4-13.

98. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994;49: 1-8.

99. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.

100. Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996;3:117-125.

101. Garcia-Dorado D, Theroux P, Tornos P, et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation 1995;92:1743-1748.

102. Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Am J Cardiol 1998;81:678-681.

103. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327:175-81.

104. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.

105. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19:671-677.

106. Klimt CR, Knatterud GL, Stamler J, Meier P, for the PARIS II Investigator Group. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7:251-269.

107. Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death myocardial infarction and stroke by prolongued antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.

108. Bleich SD, Nichols T, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.

109. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437.

110. de Bono DP, Simoons MI, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.

111. Baird SH, McBride SJ, Trouton TG, Wilson C. Low-molecular-weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction. J Am Coll Cardiol 1998;31(Suppl. A):191A.

112. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649.

113. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.

114. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1428.

115. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.

116. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.

117. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effect of lisino-pril and trasdermal glyceryl trinitrate sinly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.

118. ISIS-4 Collaborative Group. ISIS-4: randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.

119. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac Study(CCS-1). Lancet 1995;345:686-687.

120. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-1629.

121. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-1762.

122. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary agioplasty for acute myocardial infarction. Am J Cardiol 1996;77:1045-1051.

123. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.

124. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.

125. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of TIMI 14 trial. Circulation 1999;99:2720-2732.

126. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ilb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.

127. DeBusk RF, Blomqvist CG, Kouchoukos NT, et al. Identification and treatment of low-risk patients after acute myocardial infarction and coronary bypass surgery. N Engl J Med 1986;314:161-166.

128. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-2037.

129. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable Angina/Non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.

130. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation 2000;101:2557-2567.

131. Anderson HV Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-1650.

132. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol 1997;30:133-140.

133. Cannon CP, Sharis PJ, Schweiger MJ, et al. Prospective validation of a composite end point in thrombolytic trial of acute myocardial infarction (TIMI 4 and 5). Am J Cardiol 1997;80:696-699.

134. Mueller HS, Forman SA, Manegus MA, et al. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Clinical Trial. J Am Coll Cardiol 1995;26:900-907.

135. Cannon CP. Optimizing the treatment of unstable angina. J Thromb Thrombolysis 1995;2:205-218.

136. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987;317:1361-1365.

137. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone P. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Harvard Atheroscle-osis Reversibility Project (HARP) Group. Lancet 1994;344:1182-1186.

2 Linking Biochemistry, Vascular

Biology, and Clinical Events in Acute Coronary Syndromes

Richard C. Becker, MD and Annemarie Armani, MD


Introduction Vascular Endothelium Atherosclerosis Vascular Thrombosis

Clinical Expression of Pathobiological Events Vascular Biology, Biochemistry, and Emerging Concepts in

Arterial Thrombosis References

Was this article helpful?

0 0
Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment